Chemistry Wealth Management’s T. Rowe Price Capital Appreciation Equity ETF TCAF Stock Holding History
Bought
Maintained
Sold
Other funds holding TCAF
Chemistry Wealth Management's TCAF Position: Q2 2026 in Review
Chemistry Wealth Management increased its T. Rowe Price Capital Appreciation Equity ETF (TCAF) stake by 5.5% in Q2 2026, buying an estimated $397K and bringing the position to 194,248 shares worth $7.98M. The position accounts for 1.28% of the portfolio, ranked #15.
Chemistry Wealth Management first reported a position in TCAF in Q4 2023 and has held it in 11 quarters since. 359 funds tracked by Wall St. Rank hold TCAF as of Q2 2026.
- Chemistry Wealth Management held 194,248 shares of T. Rowe Price Capital Appreciation Equity ETF worth $7.98M as of Q2 2026.
- Chemistry Wealth Management bought 10,049 T. Rowe Price Capital Appreciation Equity ETF shares in Q2 2026, an estimated $397K.
- T. Rowe Price Capital Appreciation Equity ETF made up 1.28% of Chemistry Wealth Management's portfolio in Q2 2026, its #15 holding.
- Chemistry Wealth Management first reported a position in T. Rowe Price Capital Appreciation Equity ETF in Q4 2023 and has held it in 11 quarters since.
- 359 funds tracked by Wall St. Rank held T. Rowe Price Capital Appreciation Equity ETF as of Q2 2026.
Based on Chemistry Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.